UK: New Prostate Cancer Drug Extends Life, But NICE Against Reimbursement

Posted 11 May 2012 | By Louise Zornoza 

Despite the recognized life extending benefits of Sanofi's new prostate cancer drug, Jevtana (cabazitaxel), the UK's National Institute for Health and Clinical Excellence (NICE) has recommended against reimbursement by the National Health Service (NHS) because it is not cost effective. 

The drug is used in combination with prednisone or prednisolone as a second line treatment for prostate cancer. 

In final guidance published 11 May, NICE concluded that while the drug met its "end of life considerations" policy that would allow higher reimbursement, the total cost of treatment with the new drug was not considered a cost-effective use of NHS's limited resources.

Read more:

NICE - NICE unable to endorse new treatment for prostate cancer

More Breaking News from RegLink

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Most Viewed Articles